Pfizer (NYSE:PFE) has initiated Phase 3 clinical trials on vaccine candidates for preventing pneumonia, RSV and meningitis.
20-valent pneumococcal vaccine (20vPnC): Two studies, NCT04382326 and NCT04379713,
will assess a four-dose series in healthy infants. The former is aimed
at determining immunologic non-inferiority to Prevnar 13.
RSV vaccine (RSVpreF): Study NCT04424316 is assessing the vaccine in infants born to immunized women.
Pentavalent meningococcal vaccine (MenABCWY): Study NCT04440163 is assessing the vaccine in adolescents and young adults aimed at determining non-inferiority to licensed vaccines.
https://seekingalpha.com/news/3584877-pfizer-launches-four-late-stage-studies-on-vaccine-candidates
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.